×
ADVERTISEMENT

JULY 12, 2017

Olaparib Provides PFS Benefit in Pts With HER2-Negative Breast Cancer

Chicago—Relative to single-agent chemotherapies, olaparib delays time to both first and second progression in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer, according to results of a Phase III trial. The advantage for olaparib in this study, called OlympiAD, extended to patients with triple-negative disease.

Based on these data, “olaparib [Lynparza, AstraZeneca] is probably best used early in the course of metastatic breast cancer. It helps